While partnering activities reached new highs in 2020, Chinese biopharma players found it more difficult to snatch good deals in a more competitive landscape. They now need to act faster and do more preparation work to seize partnering opportunities, panelists said at the Chinabio Partnering Forum.

Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.

Data presented at the American Society of Gene & Cell Therapy annual meeting, including: Generation Bio.

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting, including: Adagene, Antengene, Ascentage, Beigene, Eli Lilly, Innovent Biologics, Pharmabcine.

Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers.

SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers.

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting, including: Gracell, Hummingbird.

In the “The World for Asia, Asia for the World” panel discussion at the virtual Wuxi Healthcare Forum, investors and executives took note of the region’s digital capabilities for reducing R&D costs and timelines, while also calling for more harmonization on the regulatory front to empower R&D in Asia.